Q2 2021 13F Holders as of 30 Jun 2021
-
Type / Class
-
Equity / COM NEW
-
Total 13F shares
-
40,773,220
-
Share change
-
+29,701,513
-
Total reported value
-
$86,027,840
-
Put/Call ratio
-
30%
-
Price per share
-
$2.11
-
Number of holders
-
56
-
Value change
-
+$61,296,240
-
Number of buys
-
28
-
Number of sells
-
41
Institutional Holders of CATABASIS PHARMACEUTICALS IN - COM NEW as of Q2 2021
As of 30 Jun 2021,
CATABASIS PHARMACEUTICALS IN - COM NEW was held by
56 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
40,773,220 shares.
The largest 10 holders included
PERCEPTIVE ADVISORS LLC, RA CAPITAL MANAGEMENT, L.P., Fairmount Funds Management LLC, Cormorant Asset Management, LP, VR Adviser, LLC, Logos Global Management LP, CITADEL ADVISORS LLC, BOXER CAPITAL, LLC, COMMODORE CAPITAL LP, and Alyeska Investment Group, L.P..
This page lists
56
institutional shareholders reporting positions in this security
for the Q2 2021 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.